Expansion of activated T lymphocytes (CD3 + HLA/DR +) detectable in early stages of HIV-1 infection
- PMID: 1971856
- DOI: 10.1007/BF01648577
Expansion of activated T lymphocytes (CD3 + HLA/DR +) detectable in early stages of HIV-1 infection
Abstract
The phenotypic characterization of lymphocyte subsets in relation to different clinical stages of HIV infection has mainly focussed on CD4 and CD8 cells. Some reports focus on expansion of activated T lymphocytes in AIDS patients. Yet there is no detailed knowledge whether such changes occur also in earlier stages of HIV infection. In order to describe the kinetics and possible pathogenetic meaning of this subset when related to all distinct chronologic stages, we performed two-color flow cytometric lymphocyte differentiation in 173 HIV-infected patients and 30 healthy controls. All subjects were classified according to the Walter Reed (WR) system. Our results show that a significant increase of activated T lymphocytes (CD3 + HLA/DR +) occurs early, in WR1 and WR2, thus preceding the clinically relevant CD4 depletion. This increase is paralleled by an expansion of CD8 + Leu7 + cytotoxic cells. We conclude, that early changes of lymphocyte subsets are detectable in addition to inversion of the CD4/CD8 ratio. The possible pathogenetic meaning including the question of possible autoimmune mechanisms is discussed.
Similar articles
-
Defective clonogenic potential of CD8+ T lymphocytes in patients with AIDS. Expansion in vivo of a nonclonogenic CD3+CD8+DR+CD25- T cell population.J Immunol. 1990 Mar 1;144(5):1696-704. J Immunol. 1990. PMID: 2137842
-
Correlation of the percentage of activated, CD3 + DR + lymphocytes to serum neopterin level in HIV-seropositive haemophiliacs.Klin Wochenschr. 1991 Feb 26;69(4):143-5. doi: 10.1007/BF01665853. Klin Wochenschr. 1991. PMID: 1710305
-
T activation marker evaluation in ARC patients treated with AZT. Comparison with CD4+ lymphocyte count in non-progressors and progressors towards AIDS.Clin Exp Immunol. 1990 Aug;81(2):177-82. doi: 10.1111/j.1365-2249.1990.tb03314.x. Clin Exp Immunol. 1990. PMID: 1696859 Free PMC article.
-
How do CD8+ T lymphocytes control HIV replication in vivo?Res Immunol. 1989 Jan;140(1):115-8; discussion 122-3. doi: 10.1016/0923-2494(89)90016-3. Res Immunol. 1989. PMID: 2499020 Review. No abstract available.
-
Lymphocyte immunophenotyping at the Centers for Disease Control: the program and special studies.Clin Immunol Immunopathol. 1989 Jul;52(1):61-7. doi: 10.1016/0090-1229(89)90193-1. Clin Immunol Immunopathol. 1989. PMID: 2541956 Review.
Cited by
-
Peripheral blood CD3+HLADR+ cells and associated gut microbiome species predict response and overall survival to immune checkpoint blockade.Front Immunol. 2023 Aug 29;14:1206953. doi: 10.3389/fimmu.2023.1206953. eCollection 2023. Front Immunol. 2023. PMID: 37705980 Free PMC article.
-
Loss of mucosal CD4 lymphocytes is an early feature of HIV infection.Clin Exp Immunol. 1993 Jun;92(3):448-54. doi: 10.1111/j.1365-2249.1993.tb03419.x. Clin Exp Immunol. 1993. PMID: 8099858 Free PMC article.
-
Immunophenotypical alterations in a subset of patients with common variable immunodeficiency (CVID).Clin Exp Immunol. 1992 Oct;90(1):25-30. doi: 10.1111/j.1365-2249.1992.tb05826.x. Clin Exp Immunol. 1992. PMID: 1395097 Free PMC article.
-
Lymphocyte subsets as surrogate markers in antiretroviral therapy.Infection. 1991;19 Suppl 2:S103-8. doi: 10.1007/BF01644477. Infection. 1991. PMID: 1826674 Review.
-
Lymphocyte subsets in haematological patients with COVID-19: Multicentre prospective study.Transl Oncol. 2021 Jan;14(1):100943. doi: 10.1016/j.tranon.2020.100943. Epub 2020 Nov 11. Transl Oncol. 2021. PMID: 33204385 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials